Both drugs had DEGs connecting to genes related to cholesterol metabolism and peroxisome proliferator-activated receptor (PPAR) pathways in the hyperlipidemia network (Figures 3E and 3F). This evidence concerns the gene PPARA and hyperlipidemia.